Special Issue

Advanced Research in GPCR Signal Transduction and Cancer Biology

Message from the Guest Editors

Each cell shapes its architecture, drives metabolism, and modulates the transcriptome based on extracellular stimuli received from the rest of the body. The largest class of “protein sensors” are G protein coupled receptors (GPCRs) that collect thousands of stimuli with high specificity and provide cells with spatial information integrated over time. Thanks to this evolutionary conserved molecular machinery, cells undertake complex functions such as chemotaxis, vision, cardiac rhythm, and bone remodeling. This Special Issue aims to describe progress in mapping GPCR signaling and deciphering the informatic infrastructure of cancer cells from the perspective of intercepting pro-oncogenic signals. A better understanding of dynamic interactions and molecular compartmentalization of GPCRs, interacting molecules, downstream second messengers, kinases, transcription factors, etc. is expected to lead to more specific treatments and finally surpass antimitotic drugs and achieve personalized therapies.

Guest Editors

Dr. Giulio Innamorati

Department of Surgical Sciences, Dentistry, Gynecology and Pediatrics, Section of Surgery, University of Verona, 37134 Verona, Italy

Dr. Giorgio Malpeli

Department of Human Sciences and Promotion of Quality of Life, Università Telematica San Raffaele Roma, 00166 Rome, Italy

Deadline for manuscript submissions

closed (30 November 2023)

Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed

mdpi.com/si/145927

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines

Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed

mdpi.com/journal/biomedicines

MDPI

About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni
1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).